HGC019
HGC019 is a COVID-19 vaccine candidate developed by Gennova Biopharmaceuticals and HDT Biotech Corporation.[1][2][3]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Routes of administration | Intramuscular |
ATC code |
|
ReferencesEdit
- ^ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
- ^ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.
- ^ Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
Scholia has a profile for HGC019 (Q106370223). |